Understanding the patterns of acquired resistance to epidermal growth factor receptor (EGFR) TKI treatment has led to more effective combination therapy and continues to drive development of novel ...
EGFR mutations significantly influence NSCLC treatment, with osimertinib showing superior PFS over first-generation TKIs, but resistance remains a challenge. Combination therapies, such as osimertinib ...
First-line aumolertinib plus platinum-pemetrexed chemotherapy significantly improved progression-free survival (PFS) compared with aumolertinib alone in certain patients with epidermal growth factor ...
The final overall survival (OS) results of the FLAURA2 trial support osimertinib plus chemotherapy as the new first-line standard of care for EGFR-mutated non-small cell lung cancer (NSCLC), according ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results